Arbutus Biopharma Corp
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-5.1M | $169.7M | $-3.8M | $-7.7M | $2.5M | $-24.5M | $-12.5M | $-19.7M |
| Depreciation & Amortization | $11.0K | $11.0K | — | $11.0K | $11.0K | $330.0K | — | $336.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.6M | $1.4M | $1.3M | $1.3M | $864.0K | $3.6M | $1.6M | $2.2M |
| Net Cash from Operating Activities | $-6.0M | $-8.1M | $-4.7M | $-5.8M | $-15.7M | $-13.4M | $-10.3M | $-20.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $0 | $0 | $0 | $0 | $86.0K | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.7M | $2.2M | $-1.4M | $-10.0M | $15.6M | $11.3M | $13.4M | $-12.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.1M | $11.6M | $1.6M | $844.0K | $453.0K | $2.8M | $1.4M | $1.8M |
| Net Change in Cash | $-4.5M | $5.7M | $-4.4M | $-15.0M | $336.0K | $746.0K | $4.5M | $-30.9M |
| Free Cash Flow | — | — | $-4.7M | $-5.8M | $-15.7M | $-13.4M | $-10.4M | $-20.7M |